Comparison of demographic variables and clinical findings with immune biomarkers in type1 diabetes
DOI:
https://doi.org/10.55629/pakjpathol.v35i3.810Abstract
Objective: To explore how demographic variables and clinical findings relate to immune biomarkers, assess their impact on glycemic control, and identify the most relevant immune biomarker for the Pakistani population with Type 1 Diabetes.
Material and Methods: This cross-sectional analytical study was conducted at Chughtai Institute of Pathology, from April 2021 to March 2022. We enrolled 130 male and female diagnosed cases of Type 1 Diabetes of age below18 years in this study. A total of 100 cases were included in the study as per defined criteria and 30 were excluded. Relevant details of demographic variables & clinical findings were noted on a predesigned proforma. 5ml whole blood was taken from each subject. All samples were analyzed for Plasma Glucose, HbA1c%, C-peptide, Anti GAD65, Anti IA2 and Anti IAA. SPSS 25.0 was used for statistical analysis.
Results: Mean age of the Demographic details of study participants was 14.2±3.6years. Majority of the study participants were male (57%). Mean height was 4.89±0.69feet, mean weight of the participants was 57.8±18.0 Kilograms, mean BMI was 27.0±7.7kg/m2and mean Fasting blood glucose level was 213.3 ±128.2 mg/dL. Majority of the participants (57%) belonged to middle socioeconomic class, had normal BMI with a poor glycemic control. When means were compared, it was found that there was a significant difference in the mean anti-GAD level, where group with poor glycemic control having higher values.
Conclusion: Anti-GAD65 is the most prevalent immune biomarker in the Pakistani population, with elevated levels linked to poor glycemic control. While low socioeconomic status correlates with worse glycemic outcomes. A targeted approach for high-risk populations may enhance clinical outcomes and alleviate financial and mental burdens for patients.
Keywords: Type 1 diabetes mellitus, GAD65, IA-2, IAA, Biomarker
References
Bavuma CM, Musafiri S, Rutayisire PC, Ng’ang’a LM, McQuillan R, Wild SH. Socio-demographic and clinical characteristics of diabetes mellitus in rural Rwanda: time tocontextualize the interventions? A cross-sectional study. BMC Endocrine Disorders. 2020; 20: 1-0.
DOI: https://doi.org/10.1186/s12902-020-00660-y
Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee . IDF DIABETES ATLAS [Internet]. 10th edition. Brussels: International Diabetes Federation; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK581934/
Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Fard HH, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review andmeta-analysis. Health Promot Perspect. 2020; 10(2):98.
DOI: https://doi.org/10.34172%2Fhpp.2020.18
Giwa AM, Ahmed R, Omidian Z, Majety N, Karakus KE, Omer SM, et al. Current understandings of the pathogenesis of type 1 diabetes: Genetics to environment. World J Diabetes. 2020; 11(1): 13-25.
DOI: https://doi.org/10.4239/wjd.v11.i1.13
Purohit S, She JX. Biomarkers for type 1 diabetes. Int J Clin Exp Med. 2008;1(2): 98.
Primavera M, Giannini C, Chiarelli F. Prediction and prevention of type 1 diabetes. Front Endocrinol. 2020; 11: 248.
DOI: https://doi.org/10.3389/fendo.2020.00248
Yi L, Swensen AC, Qian WJ. Serum biomarkers for diagnosis and prediction of type 1 diabetes. Transl Res. 2018; 201: 13-25.
DOI: https://doi.org/10.1016/j.trsl.2018.07.009
Mathieu C, Lahesmaa R, Bonifacio E, Achenbach P, Tree T. Immunologicalbiomarkers for the development and progression of type 1 diabetes. Diabetologia. 2018; 61: 2252-8.
DOI: https://doi.org/10.1007/s00125-018-4726-8
Global report on diabetes [Internet]. World Health Organization. World HealthOrganization; [cited 202 3 Mar 31].
Available at: https://www.who.int/publications-detail-redirect/9789241565257
Fawwad A, Ahmedani MY, Basit A. Integrated and comprehensive care of peoplewith type 1 diabetes in a resource poor environment-“Insulin My Life (IML)” project. Int J Adv Res. 2017; 5(4): 1339-42.
DOI: http://dx.doi.org/10.21474/IJAR01/3952
Hamadi GM. Immunological markers in type 1 diabetes mellitus in Thi-Qar province, southern Iraq. J Med Life. 2022; 15(10): 1234-9.
DOI: https://doi.org/10.25122/jml-2021-0387
Mathieu C, Lahesmaa R, Bonifacio E, Achenbach P, Tree T. Immunologicalbiomarkers for the development and progression of type 1 diabetes. Diabetologia. 2018; 61: 2252-8.
DOI: https://doi.org/10.1007/s00125-018-4726-8
Tatti P, Pavandeep S. Gender difference in type 1 diabetes: An underevaluated dimension of the disease. Diabetol.2022; 3(2): 364-8.
DOI: https://doi.org/10.3390/diabetology3020027
Talbo MK, Katz A, Dostie M, Legault L, Brazeau AS. Associations between socioeconomic status and patient experience with type 1 diabetes management and complications: Cross-sectional analysis of a cohort from Québec, Canada. Can J Diabetes. 2022; 46(6): 569-77.
DOI: https://doi.org/10.1016/j.jcjd.2022.02.008
Martin C, Boudaoud AA, Poghosyan T, Zhu J, Larger E, Greenfield JR, et al. Prevalence of anti-GAD and IA2 autoantibodies in a French cohort of patients with diabetes eligible for bariatric surgery. Diabetes Metabol. 2020; 46(5): 407-9.
DOI: https://doi.org/10.1016/j.diabet.2019.12.004
Hamed MS, Samy M, Mahmoud H, Yehia N. Study of the difficult glycemic control inrelation to the presence of diabetes-autoantibodies in a sample of Egyptians with type 1 diabetes. Diabetes Res Clin Pract. 2019; 152: 53-7.
DOI: https://doi.org/10.1016/j.diabres.2019.04.026
Bravis V, Kaur A, Walkey HC, Godsland IF, Misra S, Bingley PJ, et al. Relationship between isletautoantibody status and the clinical characteristics of children and adults with incident type 1 diabetes in a UK cohort. BMJ Open. 2018; 8(4): e020904.
DOI: https://doi.org/10.1136/bmjopen-2017-020904
Kuusela S, Keskinen P, Pokka T, Knip M, Ilonen J, Vähäsalo P, et al. Extendedfamily history of type 1 diabetes in HLA‐predisposed children with and without islet autoantibodies. Pediatr Diabetes. 2020; 21(8): 1447-56.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Hafiz Muhammad Bilal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
